Back to Search
Start Over
LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis.
- Source :
-
Annals of Oncology . Nov2022 Suppl 9, Vol. 33, pS1454-S1455. 2p. - Publication Year :
- 2022
- Subjects :
- *HEPATOCELLULAR carcinoma
*SORAFENIB
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 160398010
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.10.100